Alpha 2.0
Login Register
» Articles » PMID: 25964858

Targeting Hypoxia at the Forefront of Anticancer Immune Responses

Overview
Journal Oncoimmunology
Specialty Allergy & Immunology
Date 2015 May 13
PMID 25964858
Citations 39
Authors
Muhammad Zaeem Noman
Salem Chouaib
Affiliations
Soon will be listed here.
Abstract

Hypoxia influences immune checkpoint receptors and their respective ligands. In support, we recently demonstrated that hypoxia selectively upregulates programmed cell death ligand 1 (PD-L1) on myeloid-derived suppressor cells (MDSCs) via hypoxia inducible factor 1 α (HIF-1α) binding to a hypoxia-response element (HRE) in the PD-L1 proximal promoter. Furthermore, blockade of PD-L1 under hypoxic conditions enhanced MDSC-mediated T-cell activation by attenuating MDSC secretion of IL-6 and IL-10.

Citing Articles

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy.

Li J, Ma Y, Wu Q, Ping P, Li J, Xu X Front Oncol. 2024; 14:1488730.

PMID: 39735605 PMC: 11671370. DOI: 10.3389/fonc.2024.1488730.

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.

Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D Oncol Lett. 2023; 26(3):381.

PMID: 37559573 PMC: 10407861. DOI: 10.3892/ol.2023.13967.

Functional Imaging of Hypoxia: PET and MRI.

Perez R, Kim D, Maxwell A, Camacho J Cancers (Basel). 2023; 15(13).

PMID: 37444446 PMC: 10340779. DOI: 10.3390/cancers15133336.

Current insight into the regulation of PD-L1 in cancer.

Liu Z, Yu X, Xu L, Li Y, Zeng C Exp Hematol Oncol. 2022; 11(1):44.

PMID: 35907881 PMC: 9338491. DOI: 10.1186/s40164-022-00297-8.

Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.

Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K J Hematol Oncol. 2022; 15(1):77.

PMID: 35659268 PMC: 9166526. DOI: 10.1186/s13045-022-01292-6.

References
1.
Barsoum I, Smallwood C, Siemens D, Graham C . A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2013; 74(3):665-74. DOI: 10.1158/0008-5472.CAN-13-0992. View
2.
Gabrilovich D, Ostrand-Rosenberg S, Bronte V . Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4):253-68. PMC: 3587148. DOI: 10.1038/nri3175. View
3.
Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View
4.
Curiel T, Wei S, Dong H, Alvarez X, Cheng P, Mottram P . Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003; 9(5):562-7. DOI: 10.1038/nm863. View
5.
Noman M, Desantis G, Janji B, Hasmim M, Karray S, Dessen P . PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211(5):781-90. PMC: 4010891. DOI: 10.1084/jem.20131916. View